1. Home
  2. AVXL vs NGEN Comparison

AVXL vs NGEN Comparison

Compare AVXL & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.49

Market Cap

388.7M

Sector

Health Care

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$4.14

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AVXL
NGEN
Founded
2004
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
388.7M
317.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AVXL
NGEN
Price
$4.49
$4.14
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$22.00
N/A
AVG Volume (30 Days)
1.2M
128.3K
Earning Date
04-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$3.73
52 Week High
$13.99
$5.93

Technical Indicators

Market Signals
Indicator
AVXL
NGEN
Relative Strength Index (RSI) 55.96 37.03
Support Level $3.60 $3.73
Resistance Level $4.88 $4.50
Average True Range (ATR) 0.27 0.23
MACD 0.05 0.06
Stochastic Oscillator 78.01 45.45

Price Performance

Historical Comparison
AVXL
NGEN

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: